For older adults taking aspirin to prevent heart attacks or strokes, 50 mg per day provides the same level of protection against cardiovascular events as 100 mg, but causes fewer cases of bleeding and stomach problems.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of randomized trials would determine whether 50 mg aspirin consistently provides equivalent cardiovascular protection and reduced bleeding risk compared to 100 mg across diverse elderly populations.
A systematic review and meta-analysis of all published randomized controlled trials comparing 50 mg versus 100 mg daily aspirin in adults aged 60+ with or without established cardiovascular disease, including at least 10,000 participants with minimum 2-year follow-up, measuring MACE and major bleeding as primary endpoints, with subgroup analyses by sex, renal function, and concomitant medication use.
A randomized trial would determine whether assigning older adults to 50 mg versus 100 mg aspirin directly causes differences in bleeding risk without compromising cardiovascular protection.
A double-blind, multicenter RCT of 5,000 adults aged 60–85 with cardiovascular risk factors or established CVD, randomized 1:1 to 50 mg or 100 mg aspirin daily for at least 3 years, with primary endpoints of first MACE and first major bleeding (BARC ≥3), and secondary endpoints of gastrointestinal events and all-cause mortality, stratified by renal function and concomitant anticoagulant use.
A longer-term prospective cohort with more complete follow-up could strengthen the observed association between aspirin dose and bleeding risk by reducing confounding and capturing delayed events.
A prospective multicenter cohort of 10,000 adults aged 60+ prescribed aspirin for primary or secondary prevention, with annual assessments of aspirin dose, adherence, comorbidities, and outcomes over 5 years, using standardized event adjudication and adjusting for time-varying confounders such as medication changes and renal function decline.
A case-control study could assess whether prior exposure to 50 mg versus 100 mg aspirin is more common among individuals who later experienced major bleeding, helping to identify dose-dependent risk patterns.
A nested case-control study within the LAPIS cohort comparing 200 patients with major bleeding (BARC ≥3) to 400 matched controls without bleeding, assessing prior aspirin dose, duration, and concomitant medications, with exposure data collected prospectively and blinded to outcome.
A cross-sectional analysis could describe the prevalence of bleeding symptoms among older adults currently taking 50 mg versus 100 mg aspirin, but cannot determine temporal sequence or causality.
A nationwide survey of 15,000 adults aged 60+ in China taking aspirin, collecting self-reported bleeding events, gastrointestinal symptoms, and current aspirin dose at a single time point, with validation of aspirin use via pharmacy records.